Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ...

In the ENBALV study, it was inconclusive whether edoxaban is a better treatment than warfarin for patients with early ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been ...

The study, presented Saturday at a meeting of the American Heart Association in Chicago, is the first large trial to ...